IT1274350B - Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 - Google Patents

Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Info

Publication number
IT1274350B
IT1274350B ITRM940794A ITRM940794A IT1274350B IT 1274350 B IT1274350 B IT 1274350B IT RM940794 A ITRM940794 A IT RM940794A IT RM940794 A ITRM940794 A IT RM940794A IT 1274350 B IT1274350 B IT 1274350B
Authority
IT
Italy
Prior art keywords
antagonists
consist
interface
soluble forms
interleuchina
Prior art date
Application number
ITRM940794A
Other languages
English (en)
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to ITRM940794A priority Critical patent/IT1274350B/it
Publication of ITRM940794A0 publication Critical patent/ITRM940794A0/it
Priority to CA002177837A priority patent/CA2177837A1/en
Priority to AU41866/96A priority patent/AU4186696A/en
Priority to JP8517466A priority patent/JPH09503232A/ja
Priority to CN95191457A priority patent/CN1139933A/zh
Priority to PCT/IT1995/000208 priority patent/WO1996017869A2/en
Priority to EP95940401A priority patent/EP0742794A1/en
Publication of ITRM940794A1 publication Critical patent/ITRM940794A1/it
Application granted granted Critical
Publication of IT1274350B publication Critical patent/IT1274350B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Si tratta di antagonisti di interleuchina-6, caratterizzati dal fatto di consistere di forme solubili del recettore ? di IL-6 umana (shIL-6R?) contenenti una o più mutazioni nell'interfaccia che si lega a gp 130. In una variante preferita, le mutazioni sono presenti in una posizione scelta dal gruppo comprendente Ala 228, Asn 230, His 280 e Asp 281. Questi antagonisti possono essere usati come agenti capaci di prevenire e curare malattie causate da una anormale attività di IL-6.La figura 4 mostra l'attività antagonistica del mutante Ala228Asp/Asn230Asp/His280Ser/Asp281Val in confronto alle proprietà agonistiche di shIL-6R? di tipo selvatico. Questo antagonista può essere usato per la preparazione di farmaci per la prevenzione, il controllo e la cura delle malattie dovute ad una anormale bioattività di IL-6.
ITRM940794A 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 IT1274350B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
CA002177837A CA2177837A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
JP8517466A JPH09503232A (ja) 1994-12-06 1995-12-05 ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト
CN95191457A CN1139933A (zh) 1994-12-06 1995-12-05 由在GP130结合介面突变的白细胞介素-6(IL-6)受体α的可溶形式组成的IL-6拮抗剂
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
EP95940401A EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Publications (3)

Publication Number Publication Date
ITRM940794A0 ITRM940794A0 (it) 1994-12-06
ITRM940794A1 ITRM940794A1 (it) 1996-06-06
IT1274350B true IT1274350B (it) 1997-07-17

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Country Status (7)

Country Link
EP (1) EP0742794A1 (it)
JP (1) JPH09503232A (it)
CN (1) CN1139933A (it)
AU (1) AU4186696A (it)
CA (1) CA2177837A1 (it)
IT (1) IT1274350B (it)
WO (1) WO1996017869A2 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
WO2000025745A2 (en) * 1998-11-05 2000-05-11 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
ES2319340T3 (es) * 1995-09-28 2009-05-06 Yeda Research And Development Co., Ltd. Peptidos sinteticos que inhiben la actividad de il-6.
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
DK1108435T3 (da) 1998-08-24 2007-02-05 Chugai Pharmaceutical Co Ltd Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
WO2001016166A2 (en) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
KR101142624B1 (ko) 2003-02-24 2012-06-15 추가이 세이야쿠 가부시키가이샤 인터루킨-6 길항제를 함유하는 척수손상 치료제
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
BRPI0415505A (pt) 2003-10-17 2006-12-12 Chugai Pharmaceutical Co Ltd agente terapêutico para mesotelioma
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AU2006305119B2 (en) 2005-10-21 2012-12-20 Chugai Seiyaku Kabushiki Kaisha Agents for treating cardiopathy
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (ja) 2005-11-25 2007-05-31 Keio University 前立腺癌治療剤
CN101370521A (zh) 2006-01-27 2009-02-18 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP7458790B2 (ja) 2018-01-31 2024-04-01 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP7439372B2 (ja) * 2018-06-21 2024-02-28 シャタック ラボ，インコーポレイテッド ヘテロ二量体タンパク質及びその使用
CA3135694A1 (en) 2019-04-17 2020-10-22 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CN110133241B (zh) * 2019-05-21 2022-05-27 中国食品药品检定研究院 一种测定重组人可溶性gp130-Fc融合蛋白生物学活性的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3363463B2 (ja) * 1991-10-02 2003-01-08 忠三 岸本 Ｉｌ−６レセプター誘導体

Also Published As

Publication number Publication date
AU4186696A (en) 1996-06-26
ITRM940794A1 (it) 1996-06-06
JPH09503232A (ja) 1997-03-31
CA2177837A1 (en) 1996-06-07
WO1996017869A3 (en) 1996-08-29
ITRM940794A0 (it) 1994-12-06
CN1139933A (zh) 1997-01-08
WO1996017869A2 (en) 1996-06-13
EP0742794A1 (en) 1996-11-20

Similar Documents

Publication Publication Date Title
IT1274350B (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
Kris et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin
Forss et al. From amalgam to composite: selection of restorative materials and restoration longevity in Finland
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
HUP0101694A1 (hu) Gyulladásos bélbetegségek kezelésére vagy megelőzésére szolgáló, hatóanyagként IL-6 antagonistát tartalmazó készítmény
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
TW200507849A (en) Methods for treating interleukin-6 related diseases
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO1999017755A3 (en) Medicaments
HUP0402270A2 (hu) [1,2,4]Triazolo[1,5-c]pirimidin-5-il-aminok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
HK1086011A1 (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2004537500A5 (it)
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
HUP0400662A2 (hu) A hosszú PTX3-pentraxin és a női termékenység
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
WO2002046221A3 (en) Human protein differentially expressed in alzheimer's disease's brain
RU98101907A (ru) Терапевтические агенты и аутоимунные заболевания
IL162482A (en) Use of the il6 – r / il – 6 chimera in the manufacture of a drug for the treatment of neuronal loss
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon

Legal Events

Date Code Title Description
0001 Granted